Therapeutic Drug Monitoring of Chelating Agent Deferoxamine for <i>β</i>-Thalassemia Major Patients

ISSN Print: 2158-284X
ISSN Online: 2158-2882
www.scirp.org/journal/ijcm
E-mail: ijcm@scirp.org

Citations

"Therapeutic Drug Monitoring of Chelating Agent Deferoxamine for β-Thalassemia Major Patients"
written by Rawa Ratha, Tagreed Altaei,
published by International Journal of Clinical Medicine, Vol.4 No.8, 2013

has been cited by the following article(s):

[1]	Ironing out Persisters? Revisiting the Iron Chelation Strategy to Target Planktonic Bacterial Persisters Harboured in Carbapenem-Resistant Escherichia coli
	Microorganisms, 2024

[2]	The Association Between Cytokines (IFN-Γ and IL-4) Gene Polymorphisms and Clinical Manifestations of Β-Thalassemia in Iraqi Patients
	NATURALISTA CAMPANO, 2024

[3]	Iron Chelation Therapy in Beta Thalassemia
	The Medical Journal of …, 2022

[4]	The association of hepcidin with some inflammatory markers in β-thalassemia major patients of Basrah Province.
	2020

[5]	The association of hepcidin with some inflammatory markers in β-thalassemia major patients of Basrah Province
	EurAsian Journal of …, 2020

[6]	Assessment of Iron Chelation Therapy Compliance among School Age Children with Thalassemia.
	2019

[1]	Deferoxamine prevents BBB disruption, neuroinflammation and apoptotic changes in early hours of ischemic reperfusion injury Neurochemistry International, 2025 DOI:10.1016/j.neuint.2025.106009

[2]	Ironing out Persisters? Revisiting the Iron Chelation Strategy to Target Planktonic Bacterial Persisters Harboured in Carbapenem-Resistant Escherichia coli Microorganisms, 2024 DOI:10.3390/microorganisms12050972